Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease

Signal Transduct Target Ther. 2021 May 29;6(1):212. doi: 10.1038/s41392-021-00628-x.

Qi Sun^#¹, Fei Ye^#², Hao Liang^#¹, Hongbo Liu^#¹, Chunmei Li³, Roujian Lu², Baoying Huang², Li Zhao², Wenjie Tan⁴, Luhua Lai^{5

6}

¹ BNLMS, Peking-Tsinghua Center for Life Sciences at College of Chemistry and Molecular Engineering, Peking University, Beijing, China.
² NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China CDC, Beijing, China.
³ Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
⁴ NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China CDC, Beijing, China. tanwj28@163.com.
⁵ BNLMS, Peking-Tsinghua Center for Life Sciences at College of Chemistry and Molecular Engineering, Peking University, Beijing, China. lhlai@pku.edu.cn.
⁶ Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China. lhlai@pku.edu.cn.

^# Contributed equally.

No abstract available

Publication types